Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference

to Present Clinical Development Plan for Oncology Candidate NT-219 at the

18th MIXiii-BIOMED Conference

AVIV, Israel, May 9, 2019 - Kitov Pharma Ltd. (the

"Company" or "Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class

combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor progression,

today announced that its CEO, Isaac Israel, will present at 18th MIXiii-BIOMED Conference and Exhibition, the leading annual

international healthcare industry meeting in Israel, to be held on May 14-16, 2019 in Tel Aviv, Israel. The oral presentation will

give an overview of Kitov's clinical development plans for its oncology candidate NT-219, including disclosing its first

indication for a phase 1/2 clinical trial and trial design.

NT-219 is a first-in-class small molecule dual inhibitor of

STAT3 and IRS1/2, with the potential to prevent and overcome drug resistance in various cancer types when used in combination with

Presentation Details:

Conference and Exhibition is the leading annual international healthcare industry meeting in Israel. The conference serves as a

meeting point for local and multinational companies, investors, technology transfer experts, university, research scientists, and

government representatives. This year, the focus of the conference is expanding to the full spectrum of healthcare: from prevention

to rehabilitation and everything in between. Presentations will address diagnosis, monitoring, and treatment domains, and will

explore trends and innovations that are shaping the future of the healthcare system to its full extent. Fields to be included are

gene editing and gene therapy, transforming medicine, personalized medicine and digital health, transformative cancer therapies,

prevention and rehabilitation, new modalities of cell therapies, disruptive and advanced medical devices, and cannabis therapeutics.

18th MIXiii-Biomed will take place May 14-16, 2019, at the David Intercontinental Hotel in Tel Aviv. More information can be found

at http://kenes-exhibitions.com/biomed/

Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE:

KTOV) is an innovative pharmaceutical drug development company. Leveraging deep regulatory and clinical trial expertise, Kitov's

veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development

and approval. Kitov's combination drug, Consensi , treating osteoarthritis pain and hypertension simultaneously, was

approved by the FDA for marketing in the U.S and is partnered in the U.S, China and South Korea. In addition, Kitov's NT219,

is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. Kitov

is under contract to acquire 100% of FameWave Ltd. which owns CM-24, a humanized monoclonal antibody directed against carcinoembryonic

antigen-related cell adhesion molecule 1 (CEACAM1), an immune checkpoint protein belonging to the Human CEA (Carcino-Embryonic

Antigen) protein family. CM-24 is being developed for multiple oncological indications according to the expression pattern of its

target protein. Following the recent receipt of the approval of Kitov's shareholders for the acquisition of FameWave, and

the finalization of a clinical collaboration agreement between FameWave and Bristol Myers Squibb (NYSE:BMY) for their planned Phase

1/2 clinical trials to evaluate the combination of CM-24 with nivolumab (Opdivo ), a PD-1 inhibitor, the acquisition is expected

to close during the third quarter of 2019, subject to fulfillment of certain additional closing conditions.

By lowering development risk and cost

through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential

to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content of which is

not part of this press release, please visit http://www.kitovpharma.com.

Statements and Kitov's Safe Harbor Statement

Certain statements in this press release

that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited

to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect",

"intend", "plan", "may", "should", "could", "might", "seek",

"target", "will", "project", "forecast", "continue" or "anticipate"

or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly

to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future

performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events,

and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties

and other factors that may cause our actual results, performance or achievements to be significantly different from any future

results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause

or contribute to such differences include, among others, risks relating to: the manner in which the parties to the transaction

for the acquisition of FameWave by Kitov plan to effect the transaction; the expected benefits, synergies and costs of the transaction;

management plans relating to the transaction; the expected timing of the completion of the transaction; the parties' ability

to complete the transaction considering the various closing conditions; the plans, strategies and objectives of management for

future operations; product development for NT219; the potential future financial impact of the transaction; and any assumptions

underlying any of the foregoing; the process by which early stage products such as CM-24 could potentially lead to an approved

product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact

that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully

develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack

of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation that could affect

the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products;

the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical

products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty

surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction

of competing products; patents attained by competitors; dependence on the effectiveness of our patents and other protections for

innovative products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any

patent interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such

action; and the exposure to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an

investigation by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation

on the trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory

approvals necessary in order to commercialize our products, and other factors that are discussed in our in our Annual Report on

Form 20-F for the year ended December 31, 2018 and in our other filings with the SEC, including our cautionary discussion of risks

and uncertainties under Risk Factors' in our Registration Statements and Annual Reports. These are factors that we

believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could

also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim

any intention or obligation to publicly update or revise any forward-looking statement, or other information contained herein,

whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however,

to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.govFor

further information, contact:

Deputy CEO & Chief Financial Officer

+972-3-933-3121 ext. #105

Darren Opland, Ph.D.